
Regeneron Faces Securities Class Action Over Failed Clinical Trial Data
A federal class action lawsuit now challenges Regeneron Pharmaceuticals over alleged misrepresentations regarding its Phase III Fianlimab-Libtayo study. The filing claims that investor-facing statements from company leadership artificially inflated stock prices before a sharp 13.95% decline in May 2026, leaving shareholders to grapple with significant financial losses.

























